Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Enanta Pharmaceuticals (ENTA) Income from Continuing Operations (2016 - 2025)

Enanta Pharmaceuticals' Income from Continuing Operations history spans 14 years, with the latest figure at 11938000.0 for Q4 2025.

  • For Q4 2025, Income from Continuing Operations rose 46.44% year-over-year to 11938000.0; the TTM value through Dec 2025 reached 71537000.0, up 33.06%, while the annual FY2025 figure was 81889000.0, 30.59% up from the prior year.
  • Income from Continuing Operations reached 11938000.0 in Q4 2025 per ENTA's latest filing, up from 18700000.0 in the prior quarter.
  • In the past five years, Income from Continuing Operations ranged from a high of 11938000.0 in Q4 2025 to a low of 81903000.0 in Q3 2021.
  • Average Income from Continuing Operations over 5 years is 30477750.0, with a median of 29550500.0 recorded in 2021.
  • Peak YoY movement for Income from Continuing Operations: crashed 503.91% in 2021, then soared 67.85% in 2022.
  • A 5-year view of Income from Continuing Operations shows it stood at 30115000.0 in 2021, then increased by 3.75% to 28986000.0 in 2022, then dropped by 15.25% to 33407000.0 in 2023, then skyrocketed by 33.28% to 22290000.0 in 2024, then skyrocketed by 46.44% to 11938000.0 in 2025.
  • Per Business Quant, the three most recent readings for ENTA's Income from Continuing Operations are 11938000.0 (Q4 2025), 18700000.0 (Q3 2025), and 18255000.0 (Q2 2025).